

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Bec. 1450 Alexandria, Virginia 22313-1450 (WWW.Usple.gov)

APPLICATION NO.	PILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/892,345	06/26/2001	Gregory Carlson	7651/1612	3543
7590 11/07/2003			EXAM	EXAMINER
Novartis Corporation			SERGENT,	RABON A
Corporate intellectual Property One Health Plaza, Bldg. 430 East Hanover, NJ 07936-1080			ART UNIT	PAPER NUMBER
			1731	

DATE MAILED: 11/07/2003

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/892,345	06/26/2001	Carlson	7651/1612

EXAMINER				
Sergent				
ARTUNIT	PAPER NUMBER			
1711	110303			

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

The reply filed on August 14, 2003 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): The amendment fails to comply with 37 CFR 1.121, because the claims contain amendments that have not been identified in accordance with the provisions of the rule. An example of noncompliance can be found in claims 3, 4, and 5, where polyalkylene oxide has been improperly amended to alkylene oxide. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

As a result of applicants' amendment, the following issues have been noted: Within claims 3, 4, and 5, the language, "said at least one alkylene oxide", lacks antecedent basis and within claim 46, isocyanurate and biuret have been misspelled.

Any inquiry concerning this communication should be directed to R. Sergent at telephone number (703) 308-2982.

R. Sergent

November 3, 2003

RABON SERGENT PRIMARY EXAMINER